Day: December 19, 2022

As we continue to execute our 2030 strategic plan, we have made the decision to continue to accelerate in 2023 on two key dimensions : R&D and capital expenditures. In order to maximize the long-term value of our rich R&D portfolio and in-line with our strategic priorities, we intend to boost in 2023 our R&D investment to around 8.5% of our revenues. In parallel, and in order to prepare for the future, to accompany Virbac’s growth and to increase our medium-term productivity we intend to increase our capital expenditure investments in 2023 to around €100 million. This will include possible € 20-25 million one-time real estate investments in France that will allow us to expand our footprint to prepare for the development of our operations for the next decades. Finally, we continue to execute on the other dimensions of our...

Estonian Financial Supervision and Resolution Authority granted its approval to Coop Pank AS (Coop Pank) as the acquiring company to merge with CP Varad AS, a 100% subsidiary of Coop Pank. The approval from the Estonian Financial Supervision and Resolution Authority was a precondition for the entering into force of the merger agreement concluded between Coop Pank and CP Varad AS on 17 August 2022 which means that the merger can now be completed. Earlier information published by Coop Pank about the merger is available here. As a result of the merger, CP Varad AS shall be deemed dissolved, and Coop Pank will become its successor. Since this is an intragroup merger, it will not have an impact on the consolidated financial position and rights and obligations of Coop Pank’s group. The merger is planned to be completed during the year 2022....

The total capital raised by the fund is corrected. The INVL Partner Global Infrastructure Fund I, which invests in the infrastructure fund of a world-class asset manager with a long track record, raised USD 1.28 million from 6 investors. The fund is managed by INVL, the leading investment management and life insurance group in the Baltic region. “Infrastructure is more resilient to fluctuations in value and is a long-term alternative asset class. Those who invest in this infrastructure fund not only diversify their investment risk and reduce the impact of inflation, but also benefit from the chance to invest in a global fund with the majority of its assets in the US and the UK,” says Vytautas Plunksnis, Head of Private Equity at the INVL group. Following the new offering of investment units, which ended on 16 December, the INVL Partner...

AS Harju Elekter wishes to the shareholders Happy Holidays and informs that in the year 2023, the consolidated financial results of AS Harju Elekter will be published as following: 2022 Q4 results 22 February 2023 2023 Q1 results 26 April 2023 2023 Q2 results 26 July 2023 2023 Q3 results 25 October 2023 The Annual General Meeting will be held on 28 April 2023. After their release through the stock exchange information system all Harju Elekter’s announcements are also available on company’s internet homepage at www.harjuelekter.com. Tiit Atso Chairman of the Management Board +372 674 7400 Prepared by: Marit Tack Corporate Communications Manager +372 53408444marit.tack@harjuelekter.com

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders Date        19.12.2022 Share buy-back programme – week 50 The share buy-back programme runs from and including 4 August 2022 up to and including 25 January 2023. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 369 million under a share buy-back programme, see company announcement of 5 July 2022. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme (DKK)Total in accordance with the last...

OSLO, Norway, Dec. 19, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has entered into a strategic manufacturing partnership with Richter-Helm BioLogics GmbH & Co KG to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about the strategic manufacturing partnership with Richter-Helm BioLogics. As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious growth and pipeline development,” stated Mette Husbyn, Chief Technology Officer of Nykode Therapeutics. “We are thrilled to collaborate with Nykode Therapeutics and to support the development of their leading DNA vaccine...